Caspase-cleaved TAR DNA-binding protein-43 in Pick's disease.
The hyperphosphorylation and proteolytic modification of the TAR DNA binding protein-43 (TDP-43) is a key finding in a number of neurodegenerative diseases including frontotemporal dementia with ubiquitin-positive inclusions (FTLD-U), amyotrophic lateral sclerosis (ALS), and most recently Alzheimer's disease (AD). To examine whether proteolytic modifications of TDP-43 is a relevant finding in Pick's disease, we utilized a novel site-directed caspase-cleavage antibody based upon a known caspase-3 cleavage consensus site within TDP-43 at position 219. Application of this antibody, termed TDP caspase-cleavage product (TDPccp) to postmortem Pick's disease brain sections revealed the presence of caspase-cleaved TDP-43 in Pick and Hirano bodies predominantly within region CA1 of the hippocampus. Co-localization of TDPccp with PHF-1, a general marker for Pick bodies, as well as with an antibody to caspase-cleaved tau (TauC3) was evident within the hippocampus. A semi-quantitative analysis indicated that approximately 21% and 79% of the Pick bodies identified in area CA1 contained caspase-cleaved TDP-43 or caspase-cleaved tau, respectively. Of interest was the lack of co-localization of TDPccp with PHF-1 in Pick bodies within the dentate gyrus. Collectively, these data have identified modified TDP-43 as a component of Pick and Hirano bodies that is restricted to area CA1 in Pick's disease. The relative paucity of caspase-cleaved TDP-43 found within Pick bodies in comparison to caspase-cleaved tau suggests that TDP-43 and its modification by caspases is most likely not a contributing factor leading to Pick body formation.
Rohn
Troy T
TT
Department of Biology, Boise State University, Boise, Idaho, 83725.
Kokoulina
Polina
P
Mamm Genome. 2008 May;19(5):299-305
18592312
Neuropathology. 2006 Oct;26(5):484-90
17080729
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10032-7
12888622
Biochem Biophys Res Commun. 2006 Dec 22;351(3):602-11
17084815
Neuropathol Appl Neurobiol. 1994 Feb;20(1):3-11
8208338
J Neurosci. 2007 Sep 26;27(39):10530-4
17898224
J Neuropathol Exp Neurol. 1987 Mar;46(2):185-99
3029338
Neurobiol Dis. 2002 Nov;11(2):341-54
12505426
Ann Neurol. 2007 May;61(5):435-45
17469117
Neuropathology. 2003 Dec;23(4):318-26
14719549
J Clin Invest. 2004 Jul;114(1):121-30
15232619
Acta Neuropathol. 2007 Jul;114(1):63-70
17492294
Brain Res. 2008 Sep 4;1228:189-98
18634762
Neurotherapeutics. 2008 Jul;5(3):443-57
18625456
Science. 2006 Oct 6;314(5796):130-3
17023659
J Neuropathol Exp Neurol. 2008 Jan;67(1):62-7
18091558
Brain Res. 1987 Feb 17;403(2):337-40
3103867
J Neurochem. 2008 May;105(3):797-806
18088371
Neurosignals. 2008;16(1):41-51
18097159
Neuropathol Appl Neurobiol. 2008 Feb;34(1):62-75
17971079